Percutaneous AngioVac Vegetation Extraction (PAVE) to Remove Right Heart Vegetations in Patients With Infective Endocarditis

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAngiodynamics, Inc.

About this trial

The investigation aims to demonstrate initial safety and efficacy of the AngioVac System for the removal of vegetation in the right heart in patients with infective endocarditis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Subject age ≥ 18 years

Subject provides a signed and dated Informed Consent Form

Subject has a diagnosis of native infective endocarditis

Subject has presence of bacteremia with valvular (tricuspid or pulmonic) vegetations > 1 cm confirmed by transesophageal echocardiogram (TEE) or transthoracic echocardiogram (TTE) with the presence of septic emboli

Disqualifiers

Subject requires debulking of vegetation on cardiac leads

Subject has a prior history of ischemic/hemorrhagic stroke (within 3 months)

Subject has a coagulation disorder

Subject has arterial septic emboli

Trial design

Design model

Single group

Treatments tested in this trial

  • AngioVac System

    Device

    Percutaneous vacuum-assisted aspiration of right-sided vegetation via suction, filtration and veno-venous bypass.

Treatment groups

30 Participants
are divided into 1 treatment group
Group A: AngioVac SystemExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Rate of Clinical Success

The number and proportion of patients who experience clinical success, defined as a composite of 30-day survival, absence of persistent bacteremia within 30 days post-procedure, and absence of further right-sided valve intervention through 30 days post-procedure

Time frame
30 days post-procedure
2

Rate of Major Adverse Events (MAEs)

The number and proportion of subjects who experience a MAE within 48 hours post-procedure. MAEs include: all-cause mortality, major bleeding, and device- or procedure-related adverse events of cardiac perforation, vascular perforation, dissection, or pericardial effusion/tamponade

Time frame
48 hours post-procedure

Secondary outcomes

1

Proportion of subjects completing follow-up at 30 days post-procedure

Proportion of subjects completing follow-up at 30 days post-procedure

Time frame
30 days post-procedure
2

Proportion of subjects completing follow-up at 6 months post-procedure

Proportion of subjects completing follow-up at 6 months post-procedure

Time frame
6 months post-procedure
3

Absolute change in vegetation size pre-procedure to post-procedure

Absolute change in vegetation size immediately pre-procedure to immediately post-procedure, measured by comparing imaging performed immediately pre-procedure to imaging performed immediately post-procedure (TEE)

Time frame
Periprocedural/immediately post-procedure
4

Percent change in vegetation size pre-procedure to post-procedure

Percent change in vegetation size immediately pre-procedure to immediately post-procedure, measured by comparing imaging performed immediately pre-procedure to imaging performed immediately post-procedure (TEE)

Time frame
Periprocedural/immediately post-procedure

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: